趙宏儒

【摘要】 目的 對慢性阻塞性肺疾病急性加重期患者采取低分子肝素進行治療, 分析其臨床療效。方法 86例慢性阻塞性肺疾病急性加重期患者, 按照隨機原則分為對照組與研究組, 每組43例。對照組進行常規治療, 研究組在常規治療的基礎上加以低分子肝素進行治療, 比較分析兩組療效。結果 治療前, 研究組全血粘度、血漿粘度、纖維蛋白原水平分別為(5.12±0.23)mPa·s、(1.65±0.18)mPa·s、
(5.89±0.89)g/L, 對照組全血粘度、血漿粘度、纖維蛋白原水平分別為(5.15±0.23)mPa·s、(1.63±0.14)mPa·s、
(5.79±0.64)g/L, 比較差異無統計學意義(P>0.05)。治療后, 研究組全血粘度、血漿粘度、纖維蛋白原水平分別為(3.92±0.16)mPa·s、(0.92±0.18)mPa·s、(3.85±0.23)g/L, 對照組全血粘度、血漿粘度、纖維蛋白原水平分別為(4.25±0.27)mPa·s、(1.15±0.24)mPa·s、(4.34±0.21)g/L, 研究組全血粘度、血漿粘度、纖維蛋白原水平均優于對照組, 差異具有統計學意義(t=6.895、5.027、10.317, P<0.05)。研究組總有效率97.7%高于對照組的83.7%, 差異具有統計學意義(P<0.05)。結論 針對患有慢性阻塞性肺疾病急性加重期患者開展治療時選用低分子肝素, 能夠取得良好的整體療效, 值得將在臨床推廣。
【關鍵詞】 低分子肝素;慢性阻塞性肺疾病;急性加重期
DOI:10.14163/j.cnki.11-5547/r.2018.03.046
【Abstract】 Objective To analyze the clinical efficacy of low molecular weight heparin in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods A total of 86 patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into control group and research group, with 43 cases in each group. The control group received conventional therapy, and the research group received low molecular weight heparin on the basis of conventional therapy. The efficacy in two groups was compared and analyzed. Results Before treatment, the research group had whole blood viscosity, plasma viscosity and fibrinogen level respectively as (5.12±0.23) mPa·s, (1.65±0.18)mPa·s and (5.89±0.89) g/L, which were respectively (5.15±0.23) mPa·s, (1.63±0.14) mPa·s and (5.79±0.64) g/L in the control group, and their difference was statistically significant (P>0.05). After treatment, the research group had whole blood viscosity, plasma viscosity and fibrinogen level respectively as (3.92±0.16) mPa·s, (0.92±0.18) mPa·s and (3.85±0.23) g/L,
which were respectively as (4.25±0.27) mPa·s, (1.15±0.24) mPa·s and (4.34±0.21) g/L in the control group. The research group had better whole blood viscosity, plasma viscosity and fibrinogen level than the control group, and their difference was statistically significant (t=6.895, 5.027, 10.317, P<0.05). The research group had higher total effective rate as 97.7% than 83.7% in the control group, and the difference was statistically significant (P<0.05). Conclusion For patients with acute exacerbation of chronic obstructive pulmonary disease, application of low molecular weight heparin can achieve good overall efficacy, and this method is worthy of promotion.endprint
【Key words】 Low molecular weight heparin; Chronic obstructive pulmonary disease; Acute exacerbation
慢性阻塞性肺疾病屬于一類常見的呼吸科疾病, 患者在患病后常出現咳嗽、咳痰、喘息等癥狀, 若疾病處于急性加重期時極易發生心力衰竭、猝死等情況[1-3], 對于患者的生活及生命健康造成極大的不良影響。因此, 在臨床治療中對該疾病的有效治療十分關注, 尤其是急性加重期, 本研究對患有慢性阻塞性肺疾病急性加重期的患者采取低分子肝素進行治療取得的臨床療效展開探討, 現報告如下。
1 資料與方法
1. 1 一般資料 選取2014年4月~2017年2月本院收治的86例慢性阻塞性肺疾病急性加重期患者, 經詳細診斷證實為慢性阻塞性肺疾病, 按照隨機原則將其分為對照組與研究組, 每組43例。對照……